| Follow Us:

Innovation & Job News

IR Diagnostyx looking for new ways to identify functional diseases

IR Diagnostyx is working to develop fast, accurate and painless diagnosis techniques for a variety of functional diseases like irritable bowel syndrome, interstitial cystitis (painful bladder syndrome) fibromyalgia and chronic fatigue syndrome.

Formed last year and based at TechColumbus, the company grew out of Ohio State University's Technology Entrepreneurship and Commercialization Institute at the Fisher College of Business.

Company founders -- OSU graduate students in OSU's Fisher College -- won third place in the 2008 Fisher business plan competition, says president and CEO Gary Smith. Since then, IR Diagnostyx has received a $50,000 TechGenesis grant and is currently under consideration for an additional $250,000 in funding through the TechColumbus Pre-Seed Fund.

While the company is looking for new diagnostic techniques for a variety of ailments, "we're really focused on interstitial cystitis," Smith says. "The technology's based on work done in Tony Buffington's laboratory in veterinary medicine, and that of Luis E. Rodriguez-Saona. Ironically, Luis is a food scientist, but his competency, his research area, is in infrared micro-spectroscopy."

How does that relate to the diagnosis of functional ailments?

"We take a blood sample and we're developing an algorithm, and using some complicated software we can take a look at a serum sample and see a characteristic signal generated from patients with these specific diseases," Smith explains. "And we take that diagnostic information and compare it with others and provide the physician with some feedback on the health of the patient."

The company is still in the early stages of its product development, having completed feasibility work and now preparing to launch regulatory research, Smith says.

"We're going to collect data from about 500 patients to submit to the FDA later this year," he says.

Source: Gary Smith, IR Diagnostyx
Writer: Gene Monteith

Share this page
0
Email
Print